Neil Clendeninn - OncoGenex Pharmaceuticals Independent Director

Director

Dr. Neil James Clendeninn, M.D., Ph.D., is anIndependent Director of OncoGenex Pharmaceuticals, Inc. Additionally, he has served as a member of OncoGenex Technologies Inc.s Board of Directors since September 2004. Dr. Clendeninn served as Corporationrationrate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a biopharmaceutical company and a subsidiary of Pfizer Inc., a pharmaceutical company, from 1993 until his retirement in 2001 since 2008.
Age 66
Tenure 16 years
Professional MarksPh.D
Phone425 686-1500
Webwww.oncogenex.com
Clendeninn holds a B.A. degree in biology/chemistry from Wesleyan University, and a Ph.D. degree in microbiology/pharmacology and an M.D. degree from New York University.

OncoGenex Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (35.45) % which means that it has lost $35.45 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (76.41) %, meaning that it created substantial loss on money invested by shareholders. OncoGenex Pharmaceuticals' management efficiency ratios could be used to measure how well OncoGenex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Keith MeisterYum Brands
41
Elane StockYum Brands
55
Thomas TaylorNational Vision Holdings
52
Heather CianfroccoNational Vision Holdings
45
Robert VivianShake Shack
61
Jonathan LinenYum Brands
70
Thomas RyanYum Brands
62
Edie AmesThe Cheesecake Factory
51
Erik MorrisWingstop
39
Keith BarrYum Brands
50
Stephen RothwellNational Vision Holdings
38
Felix GernburdNational Vision Holdings
30
Peter SkalaYum Brands
60
Randolph PeelerNational Vision Holdings
53
Lauren HobartYum Brands
51
Anna FielerShake Shack
48
Drew ThomsonNational Vision Holdings
44
Justin SkalaYum Brands
57
Thomas NelsonYum Brands
57
David GoebelWingstop
67
Massimo FerragamoYum Brands
58
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. OncoGenex Pharmaceuticals (OGXI) is traded on NASDAQ Exchange in USA and employs 41 people.

Management Performance

OncoGenex Pharmaceuticals Leadership Team

Elected by the shareholders, the OncoGenex Pharmaceuticals' board of directors comprises two types of representatives: OncoGenex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoGenex. The board's role is to monitor OncoGenex Pharmaceuticals' management team and ensure that shareholders' interests are well served. OncoGenex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoGenex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Cindy Jacobs, Executive Vice President Chief Medical Officer
Patricia MD, VP of Clinical Devel.
Neil Clendeninn, Independent Director
John Bencich, CFO, Vice President
Jim DeNike, IR Contact Officer
Scott Cormack, Founder, CEO and President Treasurer, Secretary and Director
Martin Mattingly, Independent Director
Stewart Parker, Independent Director
David Smith, Independent Director
Jack Goldstein, Independent Chairman of the Board

OncoGenex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoGenex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Consideration for investing in OncoGenex Stock

If you are still planning to invest in OncoGenex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoGenex Pharmaceuticals' history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Bonds Directory
Find actively traded corporate debentures issued by US companies